Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
Puma Biotechnology
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
EX-99.1
Puma Biotechnology Surging
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology
Puma's Nerlynx unleashed to fight HER2+ breast cancer with 'best case' label | Fierce Pharma
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
FLASCO / FDA Clears Puma Biotechnology's Nerlynx for Extended Adjuvant Treatment of HER2-positive Early-Stage Breast Cancer
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology Neratinib Product Launch - YouTube
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Why Puma Biotechnology, Inc. Stock Crashed 37% in March
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Pfizer Announces Agreement with Puma Biotechnology and Lyrica Success - Clinical Professionals
Mission Accomplished – 365 Days on Nerlynx – Ela K. Browder
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Why Shares in Puma Biotechnology Inc. Are Plunging | The Motley Fool
